SynthesisThe Lancet. Global health2021
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.
Synthesis in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 1,549 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Deep Sclerectomy vs Xen in Solo Procedure: Comparative Study, Efficacy and Safety Profile
Effect of Single Incision Versus Three Planned Incision to Reduce Pre-operative Astigmatism After Phacoemulsification.
Evaluation of Macular Thickness in Patients With Glaucoma in Use of Topical Prostaglandin Analogue Undergoing Trabeculectomy With Mitomycin C
Impact of ODYSight in the Management of patientS With imparairEd Visual acuitY (ODYSSEY).
Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh
Safety and Efficacy of Peribulbar Anesthesia for Pain Management in Patients With Proliferative Diabetic Retinopathy During Panretinal Photocoagulation
Who cites it
1,549 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,888 citations in OpenAlex.
- Diagnostic accuracy and reliability of portable visual field-testing devices for detecting manifest glaucomatous visual-field loss: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Visual Outcomes After Mix-and-Match Implantation of Trifocal and Extended Depth-of-Focus Intraocular Lenses: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction.Nature genetics · 2026Pooled it
- Image-Based Deep Learning for Cataract Diagnosis: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Factors that influence eye care utilization in Nigeria: a systematic review.BMC public health · 2026Pooled it
- National, regional, and provincial prevalence of age-related macular degeneration in China in 2020: an updated systematic review and modelling study.Journal of global health · 2026Pooled it
- The gut-eye axis: microbiota and their role in diabetic retinopathy: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Effects of table tennis on vision in children and adolescents: a multilevel dose-response meta-analysis.Frontiers in medicine · 2026Pooled it
- Prediction models for progression from prediabetes to diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- EQ-5D vision bolt-on in macular degeneration: associations with visual measures and effect on utility differences and cost-effectiveness of stereotactic radiotherapy.Health and quality of life outcomes · 2026Trial
- Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study.Japanese journal of ophthalmology · 2026Trial
- Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study.Japanese journal of ophthalmology · 2026Trial
- Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR).BMJ (Clinical research ed.) · 2026Trial
- Randomized comparative multicenter study assessing two dispersive viscosurgical devices for cataract surgery.Journal of cataract and refractive surgery · 2026Trial
- Visible expansion, fragile effective coverage: Using repeated eye health system assessments to interpret limited change in eye health outcomes in Sierra Leone, 2013-2025.Dialogues in health · 2026Article
- Using the Normalization Process Theory to study facilitators and barriers to sustainable implementation of artificial intelligence-based diabetic retinopathy screening in Rwanda.Dialogues in health · 2026Article
- Optimizing Mydriasis in Cataract Surgery: Efficacy and Safety of Intracameral Regimen vs Topical Cyclopentolate in RayOne EMV Implantation.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Effects of short-term moderate versus high intraocular pressure elevation on flicker-induced changes in full-field electroretinogram.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- Diagnostic Likelihood Ratios for Glaucoma Using Deep Learning-Predicted Retinal Nerve Fiber Layer Thickness from Fundus Photographs.Ophthalmology science · 2026Article
- Smoking Cessation Duration and Diabetic Microvascular Complications.JAMA network open · 2026Article
1,489 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
2 authors at 20 institutions in 34 countries.
Funding
Abstract
backgroundMany causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error.
methodsWe did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10° visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older.
findingsGlobal crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change -0·2% [95% UI -1·5 to 1·0]; 2019 prevalence 9·58 cases per 1000 people [95% IU 8·51 to 10·8], 2010 prevalence 96·0 cases per 1000 people [86·0 to 107·0]). Age-standardised prevalence of avoidable blindness decreased by -15·4% [-16·8 to -14·3], while avoidable MSVI showed no change (0·5% [-0·8 to 1·6]). However, the number of cases increased for both avoidable blindness (10·8% [8·9 to 12·4]) and MSVI (31·5% [30·0 to 33·1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 million cases [0·59-1·23]). Leading causes of MSVI were undercorrected refractive error (86·1 million cases [74·2-101·0]) and cataract (78·8 million cases [67·2-91·4]).
interpretationResults suggest eye care services contributed to the observed reduction of age-standardised rates of avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached.
fundingBrien Holden Vision Institute, Fondation Théa, The Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.